78 related articles for article (PubMed ID: 8873394)
1. Immunogenic potential of rgp120 from African HIV-1 subtype A.
Xie JM; Pestano GA; Samms M; Lee SK; Guyden J; Boto WM
Vaccine; 1996 Jul; 14(10):993-1000. PubMed ID: 8873394
[TBL] [Abstract][Full Text] [Related]
2. Relative reactivity of the V3 loop PND of HIV-1 subtypes A, B, C, D, and F with sera from selected Ugandan localities.
Riley JP; Pestano GA; Hosford K; Francis C; Xie JM; Mugyenyi P; Kataaha P; Katongole-Mbidde E; Anokbonggo WW; Guyden J
Arch Virol; 1995; 140(8):1393-404. PubMed ID: 7544970
[TBL] [Abstract][Full Text] [Related]
3. Seroreactivity of analogous antigenic epitopes in glycoprotein 120 expressed in HIV-1 subtypes A, B, C, and D.
Pestano GA; Hosford KS; Spira AI; Riley J; Xie JM; Sewankambo N; Brown L; Ho DD; Boto WM
AIDS Res Hum Retroviruses; 1995 May; 11(5):589-96. PubMed ID: 7576915
[TBL] [Abstract][Full Text] [Related]
4. A single point mutation in HIV-1 V3 loop alters the immunogenic properties of rgp120.
Lee SK; Pestano GA; Riley J; Hasan AS; Pezzano M; Samms M; Park KJ; Guyden J; Boto WM
Arch Virol; 2000; 145(10):2087-103. PubMed ID: 11087093
[TBL] [Abstract][Full Text] [Related]
5. Distribution of linear antigenic epitopes on GP120 encoded in sibling clones of novel New York HIV-1 subtype B isolates.
Riley JP; Pestano GA; Harewood K; Alfred LJ; Guyden J; Boto WM
Cell Mol Biol (Noisy-le-grand); 1995; 41 Suppl 1():S83-91. PubMed ID: 8574151
[TBL] [Abstract][Full Text] [Related]
6. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
Boudet F; Girard M; Theze J; Zouali M
Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
[TBL] [Abstract][Full Text] [Related]
7. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
8. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
[TBL] [Abstract][Full Text] [Related]
9. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
[TBL] [Abstract][Full Text] [Related]
10. Independent divergences in the CD4 binding site and V3 loop encoded in two seroprevalent Ugandan HIV-1 clinical isolates.
Pestano G; Prince A; Guyden J; Ntambi JM; Atkin A; Boto WM
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):872-80. PubMed ID: 7686222
[TBL] [Abstract][Full Text] [Related]
11. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins.
Neurath AR; Jiang S; Strick N; Kolbe H; Kieny MP; Muchmore E; Girard M
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):813-23. PubMed ID: 1720628
[TBL] [Abstract][Full Text] [Related]
12. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
[TBL] [Abstract][Full Text] [Related]
14. Comparison of nucleic acid and protein immunization for induction of antibodies specific for HIV-1 gp120.
Peet NM; McKeating JA; Ramos B; Klonisch T; De Souza JB; Delves PJ; Lund T
Clin Exp Immunol; 1997 Aug; 109(2):226-32. PubMed ID: 9276516
[TBL] [Abstract][Full Text] [Related]
15. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles.
von Brunn A; Brand M; Reichhuber C; Morys-Wortmann C; Deinhardt F; Schödel F
Vaccine; 1993; 11(8):817-24. PubMed ID: 7689283
[TBL] [Abstract][Full Text] [Related]
16. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
Sherefa K; Sällberg M; Sönnerborg A
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
[TBL] [Abstract][Full Text] [Related]
17. Presence of multiple genetic subtypes of human immunodeficiency virus type 1 proviruses in Uganda.
Bruce C; Clegg C; Featherstone A; Smith J; Biryahawaho B; Downing R; Oram J
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1543-50. PubMed ID: 7888209
[TBL] [Abstract][Full Text] [Related]
18. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
[TBL] [Abstract][Full Text] [Related]
19. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies.
Kim YB; Han DP; Cao C; Cho MW
Virology; 2003 Jan; 305(1):124-37. PubMed ID: 12504547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
